The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

 

Market Overview

The glucagon-like peptide 1 (GLP-1) market has shown robust growth in recent years, reflecting its critical role in diabetes management.

• 2023 Market Size: $19.51 billion
• 2024 Projected Size: $21.01 billion
• CAGR (2023-2024): 7.7%

 

Historical Growth Factors

Several factors have contributed to the historical growth of the GLP-1 market:

• Rising Prevalence of Diabetes: Increasing number of diabetes cases globally.
• Improved Diabetes Management: Enhanced focus on effective diabetes control.
• Patient Preference for Injectable Therapies: High acceptance of injectable treatments.
• Clinical Efficacy and Safety Profiles: Proven effectiveness and safety of GLP-1 therapies.
• Advancements in Diabetes Research: Ongoing research and development in diabetes treatments.

 

Future Market Projections

The GLP-1 market is expected to continue its strong growth trajectory over the next few years.

• 2028 Market Size: $28.17 billion
• CAGR (2024-2028): 7.6%

 

View More On The Glucagon-like Peptide 1 Market Report 2024 – https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

 

Future Growth Drivers

Several factors are poised to drive future growth in the GLP-1 market:

• Emergence of Oral GLP-1 Therapies: Introduction of oral medications.
• Personalized Medicine: Tailored treatments based on individual needs.
• Integration in Diabetes Treatment Algorithms: Greater inclusion in treatment protocols.
• Patient-Centric Healthcare: Focus on patient preferences and outcomes.

 

Emerging Trends

Key trends that will shape the future of the GLP-1 market include:

• Market Expansion in Emerging Economies: Growing demand in developing regions.
• Regulatory Approvals for New Formulations: Introduction of new and improved treatments.
• Focus on Personalized Medicine: Customized treatment plans for better outcomes.
• Patient Education and Awareness Programs: Enhanced efforts to educate patients about diabetes management.
• Competitive Landscape Dynamics: Increased competition and innovation among market players.

 

Escalating Diabetes Prevalence Drives Market Growth

The increasing prevalence of diabetes is a major driver of the GLP-1 market.

• Global Diabetes Prevalence: Estimated at 10.5% (536.6 million people) in 2021, expected to rise to 12.2% (783.2 million) by 2045 (National Library of Medicine).

 

Major Market Players

Key companies operating in the GLP-1 market include:

• Novo Nordisk A/S
• Sanofi SA
• Eli Lilly and Co
• AstraZeneca PLC
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• F Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Baxter
• Hikma Pharmaceuticals PLC

 

Technological Innovations

Innovation remains a cornerstone of the GLP-1 market’s growth.

• Novo Nordisk: Launched Wegovy, a once-weekly GLP-1 therapy for weight management, demonstrating safety and efficacy in clinical trials.

 

Strategic Acquisitions

Acquisitions are driving market expansion and innovation.

• Eli Lilly: Acquired Protomer Technologies for approximately $1 billion in July 2021, enhancing its portfolio with next-generation protein therapeutics.

 

Market Segmentation

The GLP-1 market is segmented by product, route of administration, and end-users.

1. By Product:
   • Trulicity
   • Ozempic
   • Victoza
   • Rybelsus
   • Other Types
2. By Route of Administration:
   • Oral
   • Parenteral
   • Other Routes
3. By End-Users:
   • Hospitals
   • Specialty Clinics
   • Other End Users

 

Regional Insights

Regional dynamics play a significant role in the GLP-1 market.

• North America: Largest region in the market in 2023, driven by high diabetes prevalence and advanced healthcare infrastructure.

 

Conclusion

The GLP-1 market is set for continued strong growth, driven by rising diabetes prevalence, technological innovations, and strategic industry moves. With a focus on personalized medicine and expanding into emerging economies, the market is poised to play a crucial role in diabetes management and treatment in the coming years.

 

Request A Sample Of The Global Glucagon-like Peptide 1 Market Report 2024:

https://www.thebusinessresearchcompany.com/sample_request?id=10830&type=smp

 

The Glucagon-like Peptide 1 Global Market Report 2024  provides comprehensive insights on the glucagon-like peptide 1 market size, trends and drivers, opportunities, strategies, and competitor analysis. The countries covered in the glucagon-like peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

 

View More Related Reports –

Biosimilar Growth Hormones Global Market Report 2024

Parathyroid Hormone Global Market Report 2024

Biosimilar Hormones Global Market Report 2024

 

Learn More About The Business Research Company
The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

 

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

 

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model